Drug Type Small molecule drug |
Synonyms KC 1086, KC1086 |
Target |
Action inhibitors |
Mechanism KAT6A inhibitors(lysine acetyltransferase 6A inhibitors), KAT6B inhibitors(lysine acetyltransferase 6B inhibitors), KAT7 inhibitors(lysine acetyltransferase 7 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Aug 2025 | |
| Metastatic Solid Tumor | Phase 1 | - | 01 Aug 2025 | |
| Relapsed Solid Neoplasm | IND Approval | China | 01 Jul 2025 | |
| Estrogen receptor positive breast cancer | Preclinical | China | 24 Apr 2026 | |
| Female Genital Neoplasms | Preclinical | China | 29 May 2024 |





